PSEN2 and Alzheimer disease: A similar study examined brain tissue in 100 AD and 52 control subjects, with no pathogenic somatic variants in APP, PSEN1, PSEN2, or other targeted genes, though additional blood samples did show scattered somatic variants, including two potentially damaging mutations in SORL1 (87).